GADL1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: 293T and K562 cell lysates, Primary antibody: P06545(GADL1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P06545(GADL1 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The glutamate decarboxylase-like protein 1 (GADL1) antibody is a tool used to detect and study GADL1. an enzyme belonging to the glutamate decarboxylase (GAD) family. Unlike its well-characterized homologs GAD65 and GAD67. which are critical for synthesizing the neurotransmitter gamma-aminobutyric acid (GABA) in the nervous system, GADL1 exhibits distinct biochemical properties and tissue expression. Primarily expressed in the kidneys, testes, and specific brain regions, GADL1 lacks classical GABA-producing activity but may participate in alternative metabolic pathways, such as synthesizing β-alanine or influencing cellular redox balance.

GADL1 antibodies are pivotal in research to elucidate the protein’s physiological roles. Studies suggest potential links to neuropsychiatric disorders, metabolic conditions, and renal function, though its exact mechanisms remain unclear. In autoimmune contexts, GAD antibodies (typically targeting GAD65/67) are biomarkers for type 1 diabetes and stiff-person syndrome, but GADL1 autoantibodies are less characterized. Emerging evidence hints at their possible association with certain autoimmune or neurological conditions, warranting further investigation.

Commercially available GADL1 antibodies are used in techniques like Western blotting, immunohistochemistry, and ELISA. Validation of antibody specificity is crucial due to structural similarities among GAD family members. Ongoing research aims to clarify GADL1’s functional significance and its potential as a diagnostic or therapeutic target.